PE20221509A1 - CHO CELL THAT EXPRESSES IL-15 HETERODIMERS - Google Patents

CHO CELL THAT EXPRESSES IL-15 HETERODIMERS

Info

Publication number
PE20221509A1
PE20221509A1 PE2022001548A PE2022001548A PE20221509A1 PE 20221509 A1 PE20221509 A1 PE 20221509A1 PE 2022001548 A PE2022001548 A PE 2022001548A PE 2022001548 A PE2022001548 A PE 2022001548A PE 20221509 A1 PE20221509 A1 PE 20221509A1
Authority
PE
Peru
Prior art keywords
cho cell
heterodimers
expresses
heterodimer
15ralpha
Prior art date
Application number
PE2022001548A
Other languages
Spanish (es)
Inventor
Richard Gabriel
Thomas Jostock
Justyna Jozefczuk
Urs Ulrich Lohrig
Alexandre Aurelien Pons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20221509A1 publication Critical patent/PE20221509A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere al heterodimero de IL-15/IL-15Ralfa producido en una linea celular CHO, y metodo de produccion del heterodimero y metodo de tratamiento utilizando el heterodimero.The present invention relates to the IL-15/IL-15Ralpha heterodimer produced in a CHO cell line, and method of production of the heterodimer and method of treatment using the heterodimer.

PE2022001548A 2020-02-05 2021-01-29 CHO CELL THAT EXPRESSES IL-15 HETERODIMERS PE20221509A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
PE20221509A1 true PE20221509A1 (en) 2022-10-04

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001548A PE20221509A1 (en) 2020-02-05 2021-01-29 CHO CELL THAT EXPRESSES IL-15 HETERODIMERS

Country Status (21)

Country Link
US (1) US20210244821A1 (en)
EP (1) EP4100425A1 (en)
JP (2) JP2022522566A (en)
KR (1) KR20220137651A (en)
CN (1) CN115023436A (en)
AR (1) AR121261A1 (en)
AU (1) AU2021215893A1 (en)
BR (1) BR112022014493A2 (en)
CA (1) CA3168469A1 (en)
CL (2) CL2022002094A1 (en)
CO (1) CO2022010860A2 (en)
CR (1) CR20220367A (en)
DO (1) DOP2022000156A (en)
EC (1) ECSP22060286A (en)
IL (1) IL295278A (en)
JO (1) JOP20220174A1 (en)
MX (1) MX2022009611A (en)
PE (1) PE20221509A1 (en)
TW (1) TW202142558A (en)
UY (1) UY39062A (en)
WO (1) WO2021156720A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
US20230390361A1 (en) 2020-10-26 2023-12-07 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinoma
WO2024097918A1 (en) 2022-11-04 2024-05-10 Novartis Ag Nkg2d fusion protein cancer therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
NZ569541A (en) * 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
ES2470772T3 (en) 2007-05-11 2014-06-24 Altor Bioscience Corporation Fusion molecules and variants of IL-15
EP2326531B2 (en) 2008-08-22 2021-01-13 Magna Seating Inc. Disc recliner with reduced backlash
TWI532495B (en) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
WO2014066527A2 (en) * 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
DK3536776T3 (en) 2014-04-29 2024-01-15 Novartis Ag PREVIOUSLY UNKNOWN VERTEBRATE CELLS AND METHODS FOR RECOMBINANT EXPRESSION OF A POLYPEPTIDE OF INTEREST
CA2970385C (en) * 2014-12-19 2023-04-04 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex and use thereof
CA3032669A1 (en) * 2016-08-01 2018-02-08 William Jia Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
CN110177568A (en) * 2017-01-20 2019-08-27 诺华股份有限公司 Combination treatment for treating cancer
US20220211815A1 (en) * 2018-02-02 2022-07-07 Novartis Ag Combination therapy for the treatment of cancer
WO2019166617A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Also Published As

Publication number Publication date
CL2022002094A1 (en) 2023-03-10
CA3168469A1 (en) 2021-08-12
CO2022010860A2 (en) 2022-08-19
DOP2022000156A (en) 2022-10-16
JP2022522566A (en) 2022-04-20
AU2021215893A1 (en) 2022-08-25
JOP20220174A1 (en) 2023-01-30
IL295278A (en) 2022-10-01
AR121261A1 (en) 2022-05-04
WO2021156720A1 (en) 2021-08-12
KR20220137651A (en) 2022-10-12
CL2023002447A1 (en) 2024-03-15
MX2022009611A (en) 2022-11-07
ECSP22060286A (en) 2022-09-30
US20210244821A1 (en) 2021-08-12
CR20220367A (en) 2022-08-30
UY39062A (en) 2021-09-30
EP4100425A1 (en) 2022-12-14
BR112022014493A2 (en) 2022-09-20
TW202142558A (en) 2021-11-16
CN115023436A (en) 2022-09-06
JP2023145622A (en) 2023-10-11

Similar Documents

Publication Publication Date Title
PE20221509A1 (en) CHO CELL THAT EXPRESSES IL-15 HETERODIMERS
TWD191091S (en) Shoe upper
TWD188400S (en) Shoe upper
PE20191150A1 (en) T-CELL RECEPTORS WITH ENHANCED PAIRING
TWD197377S (en) Shoe upper
CL2019002793A1 (en) Composition for producing tagatose and method of producing tagatose using the same.
PE20181147A1 (en) DRIP EMITTER
CR20170390A (en) BICYCLE HETEROCICLES AS FGFR INHIBITORS
BR112022001207A2 (en) Method of obtaining mitochondria from cells and mitochondria obtained
AR117416A1 (en) OXADIAZOLINE DERIVATIVES
BR112017001550A2 (en) tissue graft
PH12020551663A1 (en) Genetic loci associated with increased fertility in maize
CL2022002540A1 (en) Novel compounds useful in the treatment of a disease associated with angiotensin ii
AR112587A1 (en) PSYCHOSA-6-PHOSPHATE PHOSPHATASE, COMPOSITION TO PRODUCE D-PSYCHOSA INCLUDING THE ENZYME AND METHODS TO PRODUCE D-PSYCHOSE USING THE ENZYME
MX2020003668A (en) Treatment of smc mediated disease.
BR112015018230A2 (en) method for making a shaped material, and shaped material
CO2024002924A2 (en) Nanoparticle for early development of concrete strength, composition for forming concrete, including the same, and method for producing the same
AR103042A1 (en) SUPPRESSION OF THE PARENTAL ARNI OF THE GEN KRUPPEL TO CONTROL POTEOPTER PESTS
RO133069A3 (en) Light-emitting diode lighting system and device
CL2016001634A1 (en) Bicolor mesh that prevents damage to the fruit due to the action of direct solar radiation and high temperatures.
CL2021002277A1 (en) L-shaped crosspiece. (request divisional 201903255)
ECSDI23044051S (en) NEW 50MM SYPHON MOLD
TWD193225S (en) Light emitting diode
TR201902150U5 (en) Vacuum Pool Used in Plastic Pipe Production Line
JP1709015S (en) ornament